Question 1

Factor VIII:vWF is the carrier protein of the factor VIII complex and serves to concentrate __________ present in small amounts to the site of the injury.

Accepted Answer

A)  VIII:vWF 
B)  VIII:Ag 
C)  VIII:C 
D)  All of the above 
E)  None of the above 
A)  VIII:vWF 
B)  VIII:Ag 
C)  VIII:C 
D)  All of the above 
E)  None of the above

Question 2

All of the following are characteristics of inhibitors to factor VIII:C seen in hemophilia A except:

Accepted Answer

A)  Neutralize factor VIII:C at 37°C 
B)  Temperature dependent 
C)  IgM in nature 
D)  IgG in nature 
E)  None of the above 
A)  Neutralize factor VIII:C at 37°C 
B)  Temperature dependent 
C)  IgM in nature 
D)  IgG in nature 
E)  None of the above

Question 3

How is the presence of VIII:vWF demonstrated in the laboratory?

Accepted Answer

A)  One-stage APTT 
B)  Platelet response to aggregation by ristocetin 
C)  One-stage PT 
D)  Reptilase test 
E)  None of the above 
A)  One-stage APTT 
B)  Platelet response to aggregation by ristocetin 
C)  One-stage PT 
D)  Reptilase test 
E)  None of the above

Question 4

Which rare inherited disorder results in a failure to synthesize adequate amounts of circulating fibrinogen?

Accepted Answer

A)  Afibrinogenemia 
B)  Dysfibrinogenemia 
C)  Wiskott-Aldrich syndrome 
D)  von Willebrand's disease 
E)  None of the above 
A)  Afibrinogenemia 
B)  Dysfibrinogenemia 
C)  Wiskott-Aldrich syndrome 
D)  von Willebrand's disease 
E)  None of the above

Question 5

Which laboratory tests are normal in prekallikrein deficiency?

Accepted Answer

A)  PT 
B)  TT 
C)  Bleeding time 
D)  All of the above 
E)  None of the above 
A)  PT 
B)  TT 
C)  Bleeding time 
D)  All of the above 
E)  None of the above

Question 6

What is (are) appropriate treatments in patients with hemophilia B?

Accepted Answer

A)  Prothrombin-complex concentrates 
B)  Factor IX concentrates 
C)  Fresh frozen plasma 
D)  All of the above 
E)  None of the above 
A)  Prothrombin-complex concentrates 
B)  Factor IX concentrates 
C)  Fresh frozen plasma 
D)  All of the above 
E)  None of the above

Question 7

All of the following are bleeding manifestations of vWD except:

Accepted Answer

A)  Epistaxis 
B)  Easy bruising 
C)  Hemarthrosis 
D)  Mucous membrane bleeds 
E)  None of the above 
A)  Epistaxis 
B)  Easy bruising 
C)  Hemarthrosis 
D)  Mucous membrane bleeds 
E)  None of the above

Question 8

A normal reptilase time and a prolonged thrombin time suggest the presence of __________.

Accepted Answer

A)  Calcium 
B)  Prothrombin 
C)  Heparin 
D)  Fibrinogen abnormality 
E)  None of the above 
A)  Calcium 
B)  Prothrombin 
C)  Heparin 
D)  Fibrinogen abnormality 
E)  None of the above

Question 9

All of the following are true regarding circulating anticoagulants except:

Accepted Answer

A)  They are usually immunoglobulins. 
B)  They are exogenously produced substances. 
C)  They are inhibitors of the coagulation system. 
D)  They are endogenously produced substances. 
E)  None of the above 
A)  They are usually immunoglobulins. 
B)  They are exogenously produced substances. 
C)  They are inhibitors of the coagulation system. 
D)  They are endogenously produced substances. 
E)  None of the above

Question 10

Which test(s) (is) are performed in screening for vWD?

Accepted Answer

A)  vWF activity 
B)  APTT 
C)  Bleeding time 
D)  FVIII:C level 
E)  All of the above 
A)  vWF activity 
B)  APTT 
C)  Bleeding time 
D)  FVIII:C level 
E)  All of the above

Question 11

The site of factor VIII:C synthesis may originate in all of the following except:

Accepted Answer

A)  Liver 
B)  Kidney 
C)  Endothelial cells 
D)  Megakaryocytes 
E)  None of the above 
A)  Liver 
B)  Kidney 
C)  Endothelial cells 
D)  Megakaryocytes 
E)  None of the above

Question 12

vWD is an autosomal dominant disorder characterized by decreased or absent __________ and a decrease in factor __________ secondary to the primary defect in vWF.

Accepted Answer

A)  vWF/IX 
B)  VIII:C/vWF 
C)  vWF/VIII:C 
D)  IX/VIII:C 
E)  None of the above 
A)  vWF/IX 
B)  VIII:C/vWF 
C)  vWF/VIII:C 
D)  IX/VIII:C 
E)  None of the above

Question 13

Clinical histories of patients with hemophilia A may indicate all of the following symptoms except:

Accepted Answer

A)  Hemarthroses 
B)  Postoperative bleeding 
C)  Hematuria 
D)  Hypertension 
E)  None of the above 
A)  Hemarthroses 
B)  Postoperative bleeding 
C)  Hematuria 
D)  Hypertension 
E)  None of the above

Question 14

Prothrombin complex concentrates consist of which plasma factors?

Accepted Answer

A)  II, VII, XI, XII 
B)  I, II, V, IX, X 
C)  I, IV, V, VII, XII 
D)  II, VII, IX, X 
E)  None of the above 
A)  II, VII, XI, XII 
B)  I, II, V, IX, X 
C)  I, IV, V, VII, XII 
D)  II, VII, IX, X 
E)  None of the above

Question 15

A patient with hemophilia A contains 4% VIII:C activity. This hemophilia is classified as __________.

Accepted Answer

A)  Mild 
B)  Moderate 
C)  Severe 
D)  Variable 
E)  None of the above 
A)  Mild 
B)  Moderate 
C)  Severe 
D)  Variable 
E)  None of the above

Question 16

What is the most widely accepted treatment used in hemophilia A?

Accepted Answer

A)  Cryoprecipitate 
B)  Lyophilized factor VIII concentrates 
C)  Immune globulin 
D)  Lyophilized factor IX 
E)  All of the above 
A)  Cryoprecipitate 
B)  Lyophilized factor VIII concentrates 
C)  Immune globulin 
D)  Lyophilized factor IX 
E)  All of the above

Question 17

All of the following are characteristics of lupus anticoagulants except:

Accepted Answer

A)  They are spontaneously occurring inhibitors that are immunoglobulins. 
B)  They directly react against anionic phospholipids in vitro. 
C)  They enhance the formation of the prothrombinase complex. 
D)  They prolong the phospholipid-dependent tests PT, APTT, and Russell viper venom time (RVVT). 
E)  They are associated with thrombosis problems. 
A)  They are spontaneously occurring inhibitors that are immunoglobulins. 
B)  They directly react against anionic phospholipids in vitro. 
C)  They enhance the formation of the prothrombinase complex. 
D)  They prolong the phospholipid-dependent tests PT, APTT, and Russell viper venom time (RVVT). 
E)  They are associated with thrombosis problems.

Question 18

One of the central causes of vWD is the inability of the patient's __________ to adhere to the subendothelial surfaces following injury to the blood vessel.

Accepted Answer

A)  Granulocytes 
B)  Platelets 
C)  Lymphocytes 
D)  Erythrocytes 
E)  None of the above 
A)  Granulocytes 
B)  Platelets 
C)  Lymphocytes 
D)  Erythrocytes 
E)  None of the above

Question 19

An example of a specific inhibitor is __________.

Accepted Answer

A)  Lupus anticoagulants 
B)  Antibodies to factor VIII:C 
C)  Anticardiolipin antibodies 
D)  All of the above 
E)  None of the above 
A)  Lupus anticoagulants 
B)  Antibodies to factor VIII:C 
C)  Anticardiolipin antibodies 
D)  All of the above 
E)  None of the above

Question 20

Anti-factor VIII antibodies (inhibitors) may arise:

Accepted Answer

A)  Spontaneously 
B)  In the elderly 
C)  Due to factor replacement therapy 
D)  None of the above 
E)  All of the above 
A)  Spontaneously 
B)  In the elderly 
C)  Due to factor replacement therapy 
D)  None of the above 
E)  All of the above

Exam 26: Disorders of Plasma Clotting Factors

Factor VIII:vWF is the carrier protein of the factor VIII complex and serves to concentrate __________ present in small amounts to the site of the injury.

All of the following are characteristics of inhibitors to factor VIII:C seen in hemophilia A except:

How is the presence of VIII:vWF demonstrated in the laboratory?

Which rare inherited disorder results in a failure to synthesize adequate amounts of circulating fibrinogen?

Which laboratory tests are normal in prekallikrein deficiency?

What is (are) appropriate treatments in patients with hemophilia B?

All of the following are bleeding manifestations of vWD except:

A normal reptilase time and a prolonged thrombin time suggest the presence of __________.

All of the following are true regarding circulating anticoagulants except:

Which test(s) (is) are performed in screening for vWD?

The site of factor VIII:C synthesis may originate in all of the following except:

vWD is an autosomal dominant disorder characterized by decreased or absent __________ and a decrease in factor __________ secondary to the primary defect in vWF.

Clinical histories of patients with hemophilia A may indicate all of the following symptoms except:

Prothrombin complex concentrates consist of which plasma factors?

A patient with hemophilia A contains 4% VIII:C activity. This hemophilia is classified as __________.

What is the most widely accepted treatment used in hemophilia A?

All of the following are characteristics of lupus anticoagulants except:

One of the central causes of vWD is the inability of the patient's __________ to adhere to the subendothelial surfaces following injury to the blood vessel.

An example of a specific inhibitor is __________.

Anti-factor VIII antibodies (inhibitors) may arise:

Morphology of Human Blood and Marrow Cells: Hematopoiesis

Bone Marrow

The Red Blood Cell: Structure and Function

Anemia: Diagnosis and Clinical Considerations

Evaluation of Red Blood Cell Morphology and Introduction to Platelet and White Blood Cell Morphology

Iron Metabolism and Hypochromic Anemias

Megaloblastic Anemias

Aplastic Anemia Including Pure Red Cell Aplasia and Congenital Dyserythropoietic Anemia and Paroxysmal Nocturnal Hemoglobinuria

Introduction to Hemolytic Anemias: Intracorpuscular Defects: I Hereditary Defects of the Red Cell Membrane

Hemolytic Anemias: Intracorpuscular Defects: II Hereditary Enzyme Deficiencies

Hemolytic Anemias: Intracorpuscular Defects: III the Hemoglobinopathies

Hemolytic Anemias: Intracorpuscular Defects: Iv Thalassemia

Hemolytic Anemias: Extracorpuscular Defects

Hypoproliferative Anemia: Anemia Associated With Systemic Diseases

Cell Biology, Disorders of Neutrophils, Infectious Mononucleosis, and Reactive Lymphocytosis

Introduction to Leukemia and the Acute Leukemias

Chronic Myeloproliferative Disorders I: Chronic Myelogenous Leukemia

Chronic Myeloproliferative Disorders Ii: Polycythemia Vera, Essential Thrombocythemia, and Idiopathic Myelofibrosis

Myelodysplastic Syndromes

Chronic Lymphocytic Leukemia and Related Lymphoproliferative Disorders

The Lymphomas

Multiple Myeloma and Related Plasma Cell Disorders

Lipid Lysosomal Storage Diseases and Histiocytosis

Introduction to Hemostasis

Disorders of Primary Hemostasis: Quantitative and Qualitative Platelet Disorders and Vascular Disorders

Interaction of the Fibrinolytic, Coagulation, and Kinin Systems; Disseminated Intravascular Coagulation; and Related Pathology

Introduction to Thrombosis and Anticoagulant Therapy

Quality Control in the Hematology Laboratory

Body Fluid Examination: the Qualitative, Quantitative, and Morphologic Analysis of Serous, Cerebrospinal, and Synovial Fluids

Hematology Methods

Principles of Automated Differential Analysis

Coagulation Procedures

Applications of Flow Cytometry to Hematology and Hemostasis

Molecular Diagnostic Techniques in Hematopathology

Special Stainscytochemistry

Filters

vWD is an autosomal dominant disorder characterized by decreased or absent and a decrease in factor secondary to the primary defect in vWF.